Latest Press Releases

Aspyrian therapeutics inc. ANNOUNCES SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FAST TRACK DESIGNATION GRANTED BY THE FDA, INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018

SAN DIEGO, January 16, 2018 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RM-1929...click here to continue reading

 
 

Aspyrian therapeutics inc. closes $15.1m as part of a series b-1 financing to support the advancement of its proprietary precision targeted therapy, rm-1929, to late stage clinical development and the progression of new proprietary immune oncology assets into the clinic

SAN DIEGO, July 19, 2017 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, has closed $15.1 million as part of a Series B-1 financing round expected to reach about $19 million...click here to continue reading

 

Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options

SAN DIEGO, April 27, 2017 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head & Neck Society meeting, April 27, in San Diego...click here to continue reading

 

 

Aspyrian Therapeutics Inc. closes a $40M Series B financing to advance the precision targeted cancer therapy, RM-1929, to late stage clinical development in recurrent head and neck cancer and other cancer areas.

SAN DIEGO, March 10, 2016 /PRNewswire/ -- Aspyrian Therapeutics Inc., a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform has secured $40 million as part of a Series B financing...click here to continue reading

 

 

Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Aspyrian Therapeutics Inc., a drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform, today announced the U.S. Food & Drug Administration (FDA) has accepted the Company's first Investigational New Drug (IND) application to begin clinical studies of RM-1929 for the treatment of patients with recurrent head and neck cancer...click here to continue reading

 

 

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers

SAN DIEGO, July 27, 2015 /PRNewswire/ -- Aspyrian Therapeutics Inc., a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform has secured $4.25 million as part of a Series A extension financing...click here to continue reading